Q: Kraken - Current earnings appear to show modest revenue despite a significant contract announcement some while ago, so I am wondering about the growth prospects for this company. What I would like to ask is whether the market for Kraken's products provide a good opportunity for growth or is it inherently small/limited in prospects?
Greenlane appears to be struggling to break even notwithstanding improving revenue, a (significantly?) larger backlog and what I would call an outstanding quote book which borders on the gigantic. How do you view the prospects for GRN as well as XBC, assuming they don't get Trumped like Questor?
Re DOC and WELL I have been trying to determine whether these two have the same/similar business models or not, as the more recent announcements by DOC have been on the acquisition of clinics to support a team, which appears to be a collaborative model for medical services, while WELL's emphasis appears to be on digital records and remote services. Do these two occupy the same space or are they inherently different and might one offer better prospects than the other?
Thank you for your responses.
Greenlane appears to be struggling to break even notwithstanding improving revenue, a (significantly?) larger backlog and what I would call an outstanding quote book which borders on the gigantic. How do you view the prospects for GRN as well as XBC, assuming they don't get Trumped like Questor?
Re DOC and WELL I have been trying to determine whether these two have the same/similar business models or not, as the more recent announcements by DOC have been on the acquisition of clinics to support a team, which appears to be a collaborative model for medical services, while WELL's emphasis appears to be on digital records and remote services. Do these two occupy the same space or are they inherently different and might one offer better prospects than the other?
Thank you for your responses.